Werewolf Therapeutics Q2 2024 GAAP EPS $(0.43) Misses $(0.37) Estimate, Sales $1.143M Beat $842.000K Estimate, Cash And Cash Equivalents Were $135.3M Expected To Provide Cash Runway Through At Least The First Quarter Of 2026
Portfolio Pulse from Benzinga Newsdesk
Werewolf Therapeutics reported a Q2 2024 GAAP EPS of $(0.43), missing the $(0.37) estimate. However, sales of $1.143M beat the $842K estimate. The company has $135.3M in cash and cash equivalents, expected to provide a cash runway through at least Q1 2026.
August 08, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Werewolf Therapeutics reported a Q2 2024 GAAP EPS of $(0.43), missing the $(0.37) estimate. However, sales of $1.143M beat the $842K estimate. The company has $135.3M in cash and cash equivalents, expected to provide a cash runway through at least Q1 2026.
The mixed earnings report, with an EPS miss but a revenue beat, suggests a neutral short-term impact. The strong cash position provides stability, but the EPS miss may weigh on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100